Detalles de la búsqueda
1.
Extranodal site of diffuse large B-cell lymphoma and the risk of R-CHOP chemotherapy resistance and early relapse.
Int J Clin Pract
; 74(10): e13594, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32583545
2.
Clinical Significance of BCL2, C-MYC, and BCL6 Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients.
Int J Med Sci
; 16(4): 556-566, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31171907
3.
Downregulation of hsa-miR-548d-3p and overexpression of HOXA9 in diffuse large B-cell lymphoma patients and the risk of R-CHOP chemotherapy resistance and disease progression.
Int J Lab Hematol
; 44(5): 907-917, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35830966
4.
Clinical significance of aberrant microRNAs expression in predicting disease relapse/refractoriness to treatment in diffuse large B-cell lymphoma: A meta-analysis.
Crit Rev Oncol Hematol
; 144: 102818, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31733445
Resultados
1 -
4
de 4
1
Próxima >
>>